Hemal Somaiya

Led US commercial team to develop vision, strategy and plan for a novel inline NSCLC brands in the Oncology franchise. Drove market shaping & brand building strategies & tactics. Responsible for achieving inline business, life-cycle goals, define specific business opportunities and long-term growth strategies for critical indications. Drove cross-functional alignment to support achieving long-term brand potential through appropriate funding and resourcing.

Major Responsibilities: (1) Brand Marketing: Worked on multiple launch brands supporting brand teams with informing go-to-market strategies by understanding customer behaviors, developing launch strategies, leading brand planning process, performance dashboards & strategies (2) Market Analytics: Analyzed market environment, sales trends, market penetration and competitor trends to make long-term strategic and short-term tactical recommendations to brand teams (3) Business Intelligence: Supported in-launch, growing and mature brands with market intelligence around competitor messages, channels, campaigns, managed-care strategy, KOL engagements and other field-based levers (4) War-gaming: Led 10+ workshops on launch strategies, LCM, generic threat assessments and competitor response simulations Accomplishments: (1) Delivered on projects exceeding $4M with top 10 biopharmaceutical companies (2) Managed a team of 7 team members, represented 15+ biopharmaceutical clients and attended 30+ medical conferences including ASCO, ESMO, ADA, APA and ACR every year, for competitive research, strategic analysis, customer relationship management and new business development (3) Achieved perfect client satisfaction scores in annual reviews and built strong client relationships across multiple domestic and global IMS clients

Led a team of 5 to acquire new technologies for the Zhongmei Healthcare Group (ZHG). Our team scouted over 200 novel technologies developed in the United States and performed technical reviews. The ZHG acquired several technologies based on our research.

Worked directly with the Chief Commercial Officer to design the product launch strategy for the V2 Renal Denervation System in Australia and Europe. Vessix Vascular was acquired by Boston Scientific for $425M.

Covance is a global contract research organization & drug development services company that has helped bring one-third of prescription drugs to market. At Covance, I received training in Lean Six Sigma and was responsible to help with optimizing the workflow of their Clinical Trial Strategy and Design (CTS&D) group. I led Kaizen events with a team of 10 members to map out the value stream for the current state of the workflow and suggested strategic improvements within CTS&D. I was selected for this role by the Chief Medical Officer of Covance (Ken Somberg) and reported directly to him.